Medtric Biotech was the brainchild of Connell and Schryver, who were part of a team formed through Purdue's Biomedship program. Medtric is posed to introduce a new class of wound dressings containing a revolutionary infection-fighting nanotechnology, known as Osmotec, which protects against bacteria, including antibiotic-resistant superbugs, while speeding up the healing process by 25%.

According to Schryver, "Extended hospital stays stemming from surgical site infections (SSI) represent a $7.5 billion burden for the U.S. healthcare system." There has also been a 36% jump in drug resistance over the past 20 years. Osmotec uses biomechanical principals to deactivate bacterial cells, penetrating the protective membrane of a superbug and rendering it inactive by extracting water using an osmotic pressure that also enhances wound closure.

Medtric was one of 35 teams from around the globe that participated in the competition, hosted by the LES Foundation along with the Licensing Executives Society, Inc. and LES International. The event, now in its 9th year, uniquely focuses on business plans that emphasize intellectual property assets and strategies for how these assets can best be leveraged to reach business goals. Six teams advanced to the finals, and the Purdue team was selected for the $10,000 grand prize.